olaparib
merck,astrazeneca
['propel', 'astrazeneca']
in the proffered paper session at the 2022 annual meeting, presented the results of the phase iii propel trial. get more key insights: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry